Role of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer’s Disease
Advanced Pharmaceutical Bulletin · 01.11.2023 · 13 (4) · 688-700
DOI: 10.34172/apb.2023.071 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Pharmaceutical Bulletin, online erschienen am 23.01.2023. Verfasst von Suggala Ramya Shri und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal -576104, India. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Demenz
Abstract (Originalsprache)
Glycogen synthase kinase-3 (GSK-3) was discovered to be a multifunctional enzyme involved in a wide variety of biological processes, including early embryo formation, oncogenesis, as well cell death in neurodegenerative diseases. Several critical cellular processes in the brain are regulated by the GSK-3β, serving as a central switch in the signaling pathways. Dysregulation of GSK-3β kinase has been reported in diabetes, cancer, Alzheimer’s disease, schizophrenia, bipolar disorder, inflammation, and Huntington’s disease. Thus, GSK-3β is widely regarded as a promising target for therapeutic use. The current review article focuses mainly on Alzheimer’s disease, an age-related neurodegenerative brain disorder. GSK-3β activation increases amyloid-beta (Aβ) and the development of neurofibrillary tangles that are involved in the disruption of material transport between axons and dendrites. The drug-binding cavities of GSK-3β are explored, and different existing classes of GSK-3β inhibitors are explained in this review. Non-ATP competitive inhibitors, such as allosteric inhibitors, can reduce the side effects compared to ATP-competitive inhibitors. Whereas ATP-competitive inhibitors produce disarrangement of the cytoskeleton, neurofibrillary tangles formation, and lead to the death of neurons, etc. This could be because they are binding to a site separate from ATP. Owing to their interaction in particular and special binding sites, allosteric ligands interact with substrates more selectively, which will be beneficial in resolving drug-induced resistance and also helpful in reducing side effects. Hence, in this review, we focussed on the allosteric GSK-3β inhibitors and discussed their futuristic opportunities as anti-Alzheimer’s compounds.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal -576104, India.
ORCID-Profile: Suggala Ramya Shri, Suman Manandhar, Yogendra Nayak, K Sreedhara Ranganath Pai
Zitieren
APA
Shri, S. R., Manandhar, S., Nayak, Y., & Pai, K. S. R. (2023). Role of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer’s Disease. Advanced Pharmaceutical Bulletin, 13(4), 688-700. https://doi.org/10.34172/apb.2023.071
Vancouver
Shri SR, Manandhar S, Nayak Y, Pai KSR. Role of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer’s Disease. Advanced Pharmaceutical Bulletin. 2023;13(4):688-700. doi:10.34172/apb.2023.071
BibTeX
@article{Shri2023,
author = {Shri, Suggala Ramya and Manandhar, Suman and Nayak, Yogendra and Pai, K Sreedhara Ranganath},
title = {Role of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer’s Disease},
journal = {Advanced Pharmaceutical Bulletin},
year = {2023},
volume = {13},
number = {4},
pages = {688--700},
doi = {10.34172/apb.2023.071}
}
EUVIMED